Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Mol. Neurodegener., Aug 09 2018, 13 (1) 43 | https://doi.org/10.1186/s13024-018-0276-2